Director's Share Dealing
Hong Kong, Shanghai & Florham Park, NJ - Thursday, September 14, 2023: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; SEHK:13) has received notifications that the spouse of Mr Graeme Jack, Independent Non-executive Director, sold a total of 3,000 American Depositary Shares of the Company ("ADSs", each representing five Ordinary Shares of US$0.10 each of the Company) at a price of US$14.70 per ADS on September 12, 2023.
Following the above sale of 3,000 ADSs, the holding of Mr Jack is 17,339 ADSs Note, representing approximately 0.01% of the current issued share capital of the Company.
Note: 17,339 ADSs included (i) 9,128 ADSs currently held by Mr Jack and (ii) 8,211 ADSs as beneficiary of a trust under long term incentive plan.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
|
a) |
Name |
Ms Debbie Sue Chung
| |||
| 2 | Reason for the notification | ||||
|
a) |
Position/status |
Spouse of Mr Graeme Jack, Independent Non-executive Director
| |||
|
b) |
Initial notification/Amendment
|
Initial notification
| |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
a) |
Name
|
HUTCHMED (China) Limited | |||
|
b)
|
LEI |
2138006X34YDQ6OBYE79 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
ADS each representing five Ordinary Shares of US$0.10 each
ADS ISIN: US44842L1035 | |||
|
b) |
Nature of the transaction
|
Sale of 3,000 ADSs on September 12, 2023 at a price of US$14.70 per ADS.
| |||
|
c) |
Price(s) and volume(s) |
| | | |
|
| Price(s) | Volume(s) |
| ||
|
| US$14.70 | 3,000 ADSs |
| ||
|
|
|
|
| ||
|
d) |
Aggregated information
|
N/A | ||||
|
e) |
Date of the transaction |
2023-09-12
| ||||
|
f) |
Place of the transaction |
Nasdaq Stock Market
|
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
Contacts
Investor Enquiries | |
| Mark Lee, Senior Vice President | +852 2121 8200 |
| Annie Cheng, Vice President | +1 (973) 306 4490 |
| | |
Media Enquiries |
|
| Ben Atwell / Alex Shaw, FTI Consulting | +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Zhou Yi, Brunswick | +852 9783 6894 (Mobile) |
| | |
Nominated Advisor | |
| Atholl Tweedie / Freddy Crossley / Daphne Zhang, | +44 (20) 7886 2500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.